Observe Medical ASA · OSL:OBSRV
Observe Medical ASA — Investor Presentation (March 2023)
60 slides from Observe Medical ASA's investor presentation, March 2023
Slide 1: Observe Medical Company presentation March 2023
oYeovserve medical Observe Medical Company presentation March 2023
Slide 2: Copyright and disclaimer
OBSERVE MEDICAL Copyright and disclaimer Copyright Copyright of all published material including photographs, drawings and images in this document remains vested in Observe Medical and third-party contributors as appropriate. Accordingly, neither the whole nor any part of this document shall be repr
Slide 3: Introduction
INTRODUCTION
Slide 4: Key investment highlights
INTRODUCTION Key investment highlights Powerful • Observe Medical has a powerful medtech commercialization platform 1 platform • Commercializing proprietary innovative products to capitalize on significant market opportunities • Unometer acquisition accelerates commercial roll-out of OM’s combined p
Slide 5: Observe Medical is a Nordic medtech company with global reach
INTRODUCTION Observe Medical is a Nordic medtech company with global reach Observe Medical in brief Current products and offerings • Commercializing proprietary innovative medtech Nordic distribution products on a global market • International distributor and partner network as well as Nordic direct
Slide 6: Summary of proposed acquisitions
INTRODUCTION Summary of proposed acquisitions 1 Market leading urine measurement portfolio 2 Production facility with strong track-record Unometer portfolio Ferrari L. facility • Opportunity to acquire • Opportunity to acquire market leading urine operative production measurement products facility f
Slide 7: The new strengthened medtech platform and extended distribution network
INTRODUCTION The new strengthened medtech platform and extended distribution network will accelerate commercialization of existing products PLATFORM • Commercializing proprietary innovative medtech products on a global market • International distributor and partner network and Nordic direct sales op
Slide 8: Pathway to run-rate revenue of NOK +250 million end 2023
INTRODUCTION Pathway to run-rate revenue of NOK +250 million end 2023 Monthly revenue development per product 2023 (NOKm) Annual run-rate NOK +250m Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Sippi Unometer Biim ultrasound probe Nordic distribution portfolio Ferrari L. portfolio Abdo Pressure Ru
Slide 9: Gross margin and EBITDA
INTRODUCTION Gross margin and EBITDA Gross margin per product 2023 (NOKm) 80% 60% 40% 20% 0% Sippi Biim Nordic Ferrari Abdo-Pressure Unometer EBITDA and EBITDA margin1 (NOKm) 300 255 40% 200 176 151 106 20% 82 100 52 34 0% 0 2023 -24 Run-rate end 2023 2024 2025 -100 -20% Total gross result EBITDA EB
Slide 10: Business plan to reach positive free cash flow in 2024
INTRODUCTION Business plan to reach positive free cash flow in the beginning of 2024 Illustrative free cash-flow forecast1 Illustrative sources & uses until year-end 2023 Sources: NOKm (approx.) Cash balance per end-of-year 2022 14 Bank loans in Norway & Italy 20-30 Funding H1 2023 30-50 Equity issu
Slide 11: Acquisition rationale
ACQUISITION RATIONALE
Slide 12: Key acquisition highlights
ACQUISITION RATIONALE Key acquisition highlights 1 4 Market leading Value chain control products and brand Production facility with optimal location in Verona, a Becomes Europe #1 urine Central European medtech measurement provider, cluster, allowing greater supporting adoption of new value-chain co
Slide 13: The Unometer Portfolio
1 ACQUISITION RATIONALE The Unometer Portfolio • Observe Medical is given the opportunity Unometer Safeti Plus is a closed urine drainage system, to acquire the urine measurement equipped with non-return valve and needleless sample port, portfolio from Convatec, consisting of Unometer™ used in opera
Slide 14: Strong platform expected to strengthen sales of both Sippi and Unometer
1 ACQUISITION RATIONALE Strong platform expected to strengthen sales of both Sippi® and Unometer Targeting global market potential Accelerates rollout of Sippi® Unometer’s market position NOK 4bn Market potential Strong market position with approx. 80- The acquisition of the Unometer Market trends a
Slide 15: Extending distribution network through 600+ sales channels
2 ACQUISITION RATIONALE Extending distribution network and market insights through more than 600 sales channels across over 50 countries Current Biim or Sippi New from Unometer • Strong distribution network enables Unometer and Sippi sales through more than 600 sales channels in 50+ new countries, a
Slide 16: Intake of significant revenues and strong margins with untapped potential
3 ACQUISITION RATIONALE Intake of significant revenues and strong margins with untapped potential Unometer portfolio historical revenues (NOKm) Gross profit 33% 30% 28% 30% • The Unometer portfolio has previously margin (%) relatively low margins as Convatec has discounted the Unometer portfolio to
Slide 17: Production facility with optimal location in the heart of Europe
4 ACQUISITION RATIONALE Production facility with optimal location in the heart of Europe Ferrari L. introduction Located in an Italian medtech cluster • Ferrari L. is a manufacturer active in the production and supply of single-use medical devices Ferrari L. • A reputable name in the industry, with
Slide 18: Observe Medical controls larger part of value chain with Ferrari L.
4 ACQUISITION RATIONALE Observe Medical controls larger part of value chain with Ferrari L. Addressed by proposed Ferrari L. acquisition Addressed by Observe Medical today Outsourced 1 2 3 4 5 6 7 Material sourcing Manufacturing Sterilization, packaging Sales and distribution Shipment & supply Custo
Slide 19: Major reduction in cost of goods sold
5 ACQUISITION RATIONALE Major reduction in cost of goods sold for both existing and new products Expected COGS reductions from • Acquiring Ferrari L. will allow OM to proposed transaction centralize it’s production, including both the Unometer portfolio and existing products ~40% reduction • In-hous
Slide 20: Untapped capacity beyond current production scope
6 ACQUISITION RATIONALE Untapped capacity beyond current production scope • OM aims to utilize the facility for its current product portfolio, along with production of the proposed acquired Unometer portfolio • Any potential remaining capacity can be utilized for production of third-party brands. Th
Slide 21: Sippi
SIPPI®
Slide 22: Sippi is a unique digital and automated urine meter
Sippi® is a unique digital and automated urine meter Sippi® is the first automated digital urine meter with biofilm control and wireless connectivity, initially sold to ICUs and wards Current generation of Sippi®, with wireless connectivity to patient data monitoring systems CE-marked and with propr
Slide 23: Sippi eliminates one of the last manual monitoring procedures in the ICU
Sippi® eliminates one of the last manual monitoring procedures in the ICU Addressing key burdens of current clinical practice, A unique, automated, digital urine meter with wireless representing considerable added value and cost savings data transfer and biofilm control Burdens of current Patient we
Slide 24: Significant market potential for Sippi with strong volume growth
Significant market potential for Sippi® with strong volume growth Current global market potential Further potential for optimizing hospital implementation Current focus: ~400k ~0.5M Hospital ICU beds Sippi® base units Thoracic dept. 1 surgery 8 beds: 24M +30M BU1: 10 Hospital admitted to ICU p.a. Si
Slide 25: Biim
oeovserve medical
Slide 26: Biim – Wireless ultrasound device
Biim – Wireless ultrasound device Biim’s wireless pocketable ultrasound device allow for the ability to scan patients and review images in seconds Biim makes ultrasound technology available where it has not been before, and improves patient welfare, health economics and data accuracy Biim offers nur
Slide 27: Biim's unique ultrasound probe stands out among competitors
Biim’s unique ultrasound probe stands out among competitors Biim delivers a unique device… … which clearly stands out among its competitors Ultrasound made-simple Competitor concept disadvantages: Higher level of complexity adding An intuitive and low Wireless performance challenges complexity devic
Slide 28: Extensive R&D since 2014 – agreement with Fresenius a major milestone
Extensive R&D conducted since 2014 – agreement with Fresenius a major important milestone 260x Full Fresenius US rollout Phase 1 delivery Full Fresenius Completed delivery Medical Care US Pilot study phase 1 of 260 rollout would ultrasound probes correspond to 1.1m Pilot study involving Signed LOI t
Slide 29: The dialysis market opens a huge potential for Biim
The dialysis market opens for a huge potential for Biim The market potential within dialysis is huge Fresenius partnership opens extensive growth opportunities Fresenius Medical Care is the world’s leading provider of products and There are In the global market there services for people with chronic
Slide 30: Untapped potential to distribute Biim in adjacent market segments
Significant untapped potential to distribute Biim in adjacent market segments Similar medical segments …where Biim has already established partnerships Dialysis Centres Vascular Access Teams ▪ A global provider of industry-leading medical devices used to treat cancer and peripheral vascular disease
Slide 31: Outlook
OUTLOOK Ambitions and financial targets
Slide 32: Revenue and gross profit targets by product
OUTLOOK – AMBITIONS AND FINANCIAL TARGETS Revenue and gross profit targets by product Revenue development by product Gross profit development by product (NOKm) (NOKm) 600 494 500 400 338 255 300 400 255 200 122 176 200 106 100 52 0 0 2023 Run-rate end 2023 2024 2025 2023 Run-rate end 2023 2024 2025
Slide 33: Cash flow estimate based on business plan
OUTLOOK – AMBITIONS AND FINANCIAL TARGETS Cash flow estimate based on business plan Cash flow estimate FY 2023 Cash flow estimate FY 2024 (NOKm) (NOKm) 138-218 103-105 34-44 40-50 45-115 15-80 15-80 10-15 14 Beginning Cash Financing Investment Operating Ending Cash Beginning Cash Financing Investmen
Slide 34: Outlook, priorities and next steps
OUTLOOK – AMBITIONS AND FINANCIAL TARGETS Outlook, priorities and next steps Multiple key milestones in the short and medium term, providing a highly attractive medtech story for shareholders Sippi and Biim Unometer and Ferrari L. Outlook Ambitions Continue to support Fresenius' Production readiness
Slide 35: Appendix
APPENDIX
Slide 36: Management team
APPENDIX Management team Rune Nystad Per Arne Nygård Carsten Bøgh Jørgen Mann Nilsen Jenny Wennerberg Chief Executive Officer Chief Financial Officer Chief Technology Officer Chief Commercial Officer QA & RA Director 20+ years of experience 20+ years of experience 20+ years experience from 20+ years
Slide 37: Board of Directors
APPENDIX Board of Directors Terje Bakken Sanna Rydberg Kathrine Gamborg Andreassen Line Tønnessen Eskild Endrerud Chairman of the Board Board Member Board Member Board Member Board Member Terje is a partner at Reiten Sanna is VD at Unilabs Kathrine is the CEO of Line is an Investment Eskild is CEO a
Slide 38: Largest shareholders and company structure
APPENDIX Largest shareholders as of 28 February 2023 Company structure Rank Name Number of shares % of top 20 % of total Country INGERØ REITEN INVESTMENT 1 COMPANY AS 9 653 680 29.24 % 18.05 % Norway 2 NAVAMEDIC ASA 4 222 727 12.79 % 7.89 % Norway Observe Medical ASA (Norway) 3 RO, LARS 3 340 000 10
Slide 39: Consolidated Statement of Comprehensive Income
UNAUDITED FOR THE PERIOD ENDED 31 DECEMBER 2022 Consolidated Statement of Comprehensive Income (Amounts in NOK thousand) Q4 2022 Q4 2021 FY 2022 FY 2021 Operating revenues 4 132 3 591 19 521 24 042 Cost of materials 5 113 2 519 14 344 14 524 Gross result -980 1 071 5 177 9 519 Employee benefit expen
Slide 40: Statement of financial position (1 of 2)
UNAUDITED FOR THE PERIOD ENDED 31 DECEMBER 2022 Statement of financial position (1 of 2)
Slide 41: Statement of financial position (2 of 2)
UNAUDITED FOR THE PERIOD ENDED 31 DECEMBER 2022 Statement of financial position (2 of 2)
Slide 42: Cash flow statement
UNAUDITED FOR THE PERIOD ENDED 31 DECEMBER 2022 Cash flow statement
Slide 43: Three scientific articles support the clinical value of Sippi
APPENDIX Three scientific articles have been published Protected by IPR supporting the clinical value of Sippi® portfolio 1) A. Eklund, M. Slettengren & Jan van der Linden (2015) Performance and user evaluation of a novel ▪ The Sippi® global patent situation is capacitance-based automatic urinometer
Slide 44: Pro forma financials
PRO FORMA FINANCIALS
Slide 45: Pro forma historical revenue bridge and gross margins
PRO FORMA FINANCIALS Pro forma historical revenue bridge and gross margins Illustrative pro forma revenue bridge FY 20221,2 Gross margin pro forma FY 2022 (NOKm) 80% 60% 40% 20% 0% Observe Medical Unometer Abdo-Pressure Ferrari L. Pro forma Sippi Biim Nordic Ferrari Abdo-Pressure Unometer Current 1
Slide 46: Appendix II – Financial targets by product
oeovserve medical APPENDIX Il Financial targets by product
Slide 47: Financial targets - Unometer
FINANCIAL TARGET PER PRODUCT Financial targets - Unometer Unometer - Revenue and gross margin (NOKm) 33% 43% 43% 400 314 300 197 200 134 84 100 50 16 0 2023 2024 2025 Revenue Gross result Gross margin Unometer – Sales volume (#units) Volume targets 4 139 761 4 199 953 3 921 344 3 967 235 4 000 000 2
Slide 48: Financial targets – Abdo Pressure
FINANCIAL TARGET PER PRODUCT Financial targets – Abdo Pressure Abdo Pressure - Revenue and gross margin (NOKm) 70% 87% 87% 30 23 20 20 17 20 10 4 3 0 2023 2024 2025 Revenue Gross result Gross margin Abdo Pressure – Sales volume (#units) Volume targets 84 015 63 210 65 000 63 295 55 000 56 843 12 000
Slide 49: Financial targets – Sippi
FINANCIAL TARGET PER PRODUCT Financial targets – Sippi® Accelerates rollout of Sippi® Sippi® - Revenue and gross margin Unometer’s market position (NOKm) 65% 81% 85% 78% 88% 88% 22.9 19.8 6.3 5.4 0.8 0.6 Strong market position with The acquisition of the Unometer approx. 80-90% market share in portf
Slide 50: Financial targets – Biim
FINANCIAL TARGET PER PRODUCT Financial targets – Biim Fresenius partnership opens extensive Biim - Revenue and gross margin (NOKm) growth opportunities 58% 76% 76% Fresenius Medical Care is a global healthcare company specializing in lifesaving medicines and technologies for infusion, transfusion an
Slide 51: Financial targets – Nordic
FINANCIAL TARGET PER PRODUCT Financial targets – Nordic Nordic distribution portfolio consisting of Nordic - Revenue and gross margin (NOKm) medtech devices and disposables 33% 35% 36% 27 24 20 10 8 7 2023 2024 2025 Revenue Gross result Gross margin 51
Slide 52: Financial targets – Ferrari L.
FINANCIAL TARGET PER PRODUCT Financial targets – Ferrari L. Ferrari L. - Revenue and gross margin (NOKm) 45% 49% 49% 49% 50% 50% 40 Financial targets 35 35 33 30 30 27 25 25 25 20 18 17 14 15 15 13 12 10 5 - 2020 2021 2022* 2023** 2024 2025 Revenue Gross result Gross margin *Ferrari L. guiding EUR 3
Slide 53: Financial targets - details
FINANCIAL TARGET PER PRODUCT Financial targets - details Amounts in NOK Product item Total 2023 Total 2024 Total 2025 Dec 2023 Run-rate end 2023 Sippi base unit Volum 50 600 1 800 10 120 Sippi base unit Price 6 000 6 000 6 000 6 000 6 000 Sippi base unit Cogs 1 300 700 700 1 300 1 300 Sippi base uni
Slide 54: Financial targets - details
FINANCIAL TARGET PER PRODUCT Financial targets - details Amounts in NOK Product item Total 2023 Total 2024 Total 2025 Dec 2023 Run-rate end 2023 Unometer Safeti + Volum 150 000 1 800 000 2 700 000 70 000 840 000 Unometer Safeti + Price 80 80 80 80 80 Unometer Safeti + Cogs 55 45 45 55 55 Unometer Sa
Slide 55: Financial targets - details
FINANCIAL TARGET PER PRODUCT Financial targets - details Amounts in NOK Product item Total 2023 Total 2024 Total 2025 Dec 2023 Run-rate end 2023 Abdo-Pressure stand alone Volum 9 000 30 000 35 000 1 300 15 600 Abdo-Pressure stand alone Price 340 340 340 340 340 Abdo-Pressure stand alone Cogs 98 30 3
Slide 56: Financial targets - details
FINANCIAL TARGET PER PRODUCT Financial targets - details Amounts in NOK Product item Total 2023 Total 2024 Total 2025 Dec 2023 Run-rate end 2023 Biim Ultrasound probe Volum 500 1 300 1 600 100 1 200 Biim Ultrasound probe Price 45 000 45 000 45 000 45 000 45 000 Biim Ultrasound probe Cogs 19 000 11 0
Slide 57: Appendix III – Unometer historical sales volume by country
APPENDIX III Unometer - Historical sales volume by country
Slide 58: Unometer Safeti Plus - Historical sales volume by country
Unometer Safeti Plus - Historical sales volume by country Sales volume (#units) 2019 2020 2021 2022 Germany 719 440 781 200 636 640 671 000 Italy 325 300 331 356 456 300 296 721 United Kingdom 153 360 84 460 74 490 130 520 Denmark 109 294 136 322 109 510 127 069 Australia 86 550 115 740 106 270 96 1
Slide 59: Unometer 500 - Historical sales volume by country
Unometer 500 - Historical sales volume by country Sales volume (#units) 2019 2020 2021 2022 United Kingdom 940 143 978 723 749 141 873 152 Spain 227 766 249 711 294 294 232 643 Denmark 73 416 73 472 76 160 77 411 Austria 40 110 32 340 33 992 44 725 Netherlands 63 770 45 108 34 748 45 995 Belgium 47
Slide 60: Abdo Pressure - Historical sales volume by country
Abdo Pressure - Historical sales volume by country Sales volume (#units) 2019 2020 2021 2022 Spain 13 530 14 460 14 700 16 573 Poland 6 000 4 200 7 990 18 540 Italy 6 470 8 130 8 930 10 107 Germany 7 560 10 440 7 850 8 960 France 5 740 5 920 4 960 8 827 United Kingdom 3 186 3 470 3 860 4 427 Austria